Meeting
2021 ASCO Annual Meeting
Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.
Authors
Atul Batra
All India Institute of Medical Sciences, New Delhi, India
Atul Batra , Akhil P. Santosh , Raja Pramanik , Ajay Gogia , R. M. Pandey , akash kumar , Atul Sharma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
CTRI/2021/01/030592
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS12135)
DOI
10.1200/JCO.2021.39.15_suppl.TPS12135
Abstract #
TPS12135
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Topical diclofenac in prevention of capecitabine associated HFS in patients with breast cancer: An exploratory subgroup analysis of the D-ToRCH study.
First Author: AKHIL SANTHOSH
Poster
2011 ASCO Annual Meeting
A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT).
First Author: R. C. Coombes
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.
First Author: Luhua Wang
Poster
2018 ASCO Annual Meeting
Randomized, double-blind, phase III trial of monosialotetrahexosylganglioside versus placebo in GI cancer patients with oxaliplatin induced peripheral neurotoxicity (TJMUCH-GI-001).
First Author: Zhou Likun